Elevation Oncology (ELEV) Stock Analysis

What Elevation Oncology does

Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York.

Key metrics

ETFs linked to ELEV

Broad-market and Healthcare sector ETFs an investor holding Elevation Oncology is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ELEV fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Elevation Oncology?

Elevation Oncology trades under the ticker ELEV on NASDAQ.

Which exchange is ELEV listed on?

ELEV is listed on NASDAQ.

What sector does Elevation Oncology operate in?

Elevation Oncology is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ELEV in a portfolio?

PortView shows ELEV's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.